TIL
Instil Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$5.79
−2.03%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +60.7%
- EBIT
- +59.4%
- EPS
- +65.4%
- Free cash flow
- +52.5%
- Operating cash flow
- +52.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +99.1%
Three-year CAGR
- Revenue
- —
- EBITDA
- -4.0%
- EBIT
- +28.1%
- Net income
- +3.7%
- EPS
- +6.1%
- Free cash flow
- +44.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026